An Organotypic Microcosm for the Pancreatic Tumor Microenvironment
Pancreatic duct adenocarcinoma (PDAC) is projected to become the second leading cause of cancer-related deaths in the next few years. Unfortunately, the development of novel therapies for PDAC has been challenged by a uniquely complex tumor microenvironment. The development of in vitro cancer organo...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-03-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/12/4/811 |
| _version_ | 1797626503443251200 |
|---|---|
| author | Miranda Lin Mei Gao Prakash K. Pandalai Michael J. Cavnar Joseph Kim |
| author_facet | Miranda Lin Mei Gao Prakash K. Pandalai Michael J. Cavnar Joseph Kim |
| author_sort | Miranda Lin |
| collection | DOAJ |
| description | Pancreatic duct adenocarcinoma (PDAC) is projected to become the second leading cause of cancer-related deaths in the next few years. Unfortunately, the development of novel therapies for PDAC has been challenged by a uniquely complex tumor microenvironment. The development of in vitro cancer organoids in recent years has demonstrated potential to increase therapies for patients with PDAC. Organoids have been established from PDAC murine and human tissues and they are representative of the primary tumor. Further, organoids have been shown beneficial in studies of molecular mechanisms and drug sensitivity testing. This review will cover the use of organoids to study PDAC development, invasiveness, and therapeutic resistance in the context of the tumor microenvironment, which is characterized by a dense desmoplastic reaction, hindered immune activity, and pro-tumor metabolic signaling. We describe investigations utilizing organoids to characterize the tumor microenvironment and also describe their limitations. Overall, organoids have great potential to serve as a versatile model of drug response and may be used to increase available therapies and improve survival for patients with PDAC. |
| first_indexed | 2024-03-11T10:11:20Z |
| format | Article |
| id | doaj.art-e9dc5749bc1140528d8ace0b49b40d11 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-11T10:11:20Z |
| publishDate | 2020-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-e9dc5749bc1140528d8ace0b49b40d112023-11-16T14:31:55ZengMDPI AGCancers2072-66942020-03-0112481110.3390/cancers12040811An Organotypic Microcosm for the Pancreatic Tumor MicroenvironmentMiranda Lin0Mei Gao1Prakash K. Pandalai2Michael J. Cavnar3Joseph Kim4Department of Surgery, University of Kentucky, Lexington, KY 40536, USADepartment of Surgery, University of Kentucky, Lexington, KY 40536, USADepartment of Surgery, University of Kentucky, Lexington, KY 40536, USADepartment of Surgery, University of Kentucky, Lexington, KY 40536, USADepartment of Surgery, University of Kentucky, Lexington, KY 40536, USAPancreatic duct adenocarcinoma (PDAC) is projected to become the second leading cause of cancer-related deaths in the next few years. Unfortunately, the development of novel therapies for PDAC has been challenged by a uniquely complex tumor microenvironment. The development of in vitro cancer organoids in recent years has demonstrated potential to increase therapies for patients with PDAC. Organoids have been established from PDAC murine and human tissues and they are representative of the primary tumor. Further, organoids have been shown beneficial in studies of molecular mechanisms and drug sensitivity testing. This review will cover the use of organoids to study PDAC development, invasiveness, and therapeutic resistance in the context of the tumor microenvironment, which is characterized by a dense desmoplastic reaction, hindered immune activity, and pro-tumor metabolic signaling. We describe investigations utilizing organoids to characterize the tumor microenvironment and also describe their limitations. Overall, organoids have great potential to serve as a versatile model of drug response and may be used to increase available therapies and improve survival for patients with PDAC.https://www.mdpi.com/2072-6694/12/4/811pancreatic cancerorganoidstumor microenvironment |
| spellingShingle | Miranda Lin Mei Gao Prakash K. Pandalai Michael J. Cavnar Joseph Kim An Organotypic Microcosm for the Pancreatic Tumor Microenvironment Cancers pancreatic cancer organoids tumor microenvironment |
| title | An Organotypic Microcosm for the Pancreatic Tumor Microenvironment |
| title_full | An Organotypic Microcosm for the Pancreatic Tumor Microenvironment |
| title_fullStr | An Organotypic Microcosm for the Pancreatic Tumor Microenvironment |
| title_full_unstemmed | An Organotypic Microcosm for the Pancreatic Tumor Microenvironment |
| title_short | An Organotypic Microcosm for the Pancreatic Tumor Microenvironment |
| title_sort | organotypic microcosm for the pancreatic tumor microenvironment |
| topic | pancreatic cancer organoids tumor microenvironment |
| url | https://www.mdpi.com/2072-6694/12/4/811 |
| work_keys_str_mv | AT mirandalin anorganotypicmicrocosmforthepancreatictumormicroenvironment AT meigao anorganotypicmicrocosmforthepancreatictumormicroenvironment AT prakashkpandalai anorganotypicmicrocosmforthepancreatictumormicroenvironment AT michaeljcavnar anorganotypicmicrocosmforthepancreatictumormicroenvironment AT josephkim anorganotypicmicrocosmforthepancreatictumormicroenvironment AT mirandalin organotypicmicrocosmforthepancreatictumormicroenvironment AT meigao organotypicmicrocosmforthepancreatictumormicroenvironment AT prakashkpandalai organotypicmicrocosmforthepancreatictumormicroenvironment AT michaeljcavnar organotypicmicrocosmforthepancreatictumormicroenvironment AT josephkim organotypicmicrocosmforthepancreatictumormicroenvironment |